periods of ischaemia cause some permanent damage, but useful function can return in time, perhaps implying that the myocardium has been "stunned."3 Several hours of ischaemia are necessary to produce transmural infarction and irreversible loss of function.
In man the process is more complex because the underlying cause, coronary atheroma, is generally widespread; collateral blood vessels may be present; the occlusive thrombus is dynamic and may propagate; and both spasm of the coronary arteries and increased cardiac work induced by sympathetic overactivity may temporarily exacerbate the ischaemia. Not surprisingly patients with myocardial infarction present in an untidy fashion with a stuttering history of cardiac pain and variable electrocardiographic and enzymatic changes of infarction. After the initial infarct some patients, especially those with non-transmural infarcts,4 suffer a recurrence.
Patients with coronary artery disease may develop myocardial infarction as a discrete event evolving over several hours, usually associated with coronary thrombosis,5 or through repetitive minor episodes of ischaemia, which may be detected before and after the recognised infarct. Any haemorrhagic infarction, a complication which has also been reported in man after surgical revascularisation'2 and administration of intracoronary streptokinase.'3 Phillips's use of hypothermia to preserve the myocardium in his patients is one possible explanation for this good fortune.
Reperfusion of the myocardium during acute infarction may also be achieved by catheter techniques. The lysis of coronary thrombi using intracoronary streptokinase is provoking great interest. The early results have been confirmed; four out of every five vessels occluded by thrombus can be recanalised, with improvement in the usual markers of cardiac ischaemia, including ventricular function.'4 Treatment must be started within four hours of the onset of symptoms. ' The usual method (although not the only one) by which the size ofthe sample is determined is closely related to significance testing. The objective of the procedure is to reduce to an acceptable level the risk of obtaining a misleading result by making statistical significance and clinical importance coincide as nearly as possible. The primary requirement is for the physician(s) to specify either the smallest benefit of the new treatment that would be considered to be of clinical importance or the smallest benefit that it would be important not to miss. This may not be easy, for in one sense any improvement might be worth having, but a minimum important difference can usually be specified.
For trials where the outcome measure is qualitative (or categorical)-improved or not improved, survived or diedan estimate is needed of the proportion with that outcome (such as the death rate) that may be expected in one group, usually the controls. When the measured outcome is a continuous variable such as blood pressure or lung function an estimate is needed of the standard deviation of the outcome measure. Such estimates have to be sought from previous studies or from a pilot study. Allowance should be made for the fact that participants in a trial are often a highly selected group.
The researchers must then decide with what probability (known as power) they would wish to obtain a statistically significant result if the true treatment benefit were exactly equal to the minimum important difference. They must also specify the significance level. As would be expected, the greater the power required the greater the size of the sample needed. Customarily a power of at least 80% is specified, though 90%0 is often preferable. The significance level is usually set at 5%; if a smaller level is set, such as 1%, the sample size must again be increased.
An example of this approach was reported by Hansteen et al.7 "The number of patients to be included in the study was calculated in advance to be 700. This assumption was based on an expected sudden death rate in patients taking placebo at one year of 10-120' and a calculated 50% reduction in mortality in the actively treated group. This would give an 80%/O chance of detecting a difference between the two groups significant at the 500 level (two tailed test)."
Several authors have provided graphs for the calculation of sample size for clinical trials with categorical outcome measures,8-10 and a simple nomogram is available for continuous variables.11 The calculated size of the sample refers to patients completing the trial rather than to those entering it, so that due allowance should be made for the likely drop outs. Furthermore, the sample size is calculated to allow a high probability of detecting an important therapeutic effect, if it exists, in the trial as a whole. Its ability to detect different treatment effects between subgroups will be considerably less.
Trials carried out with too few patients may easily fail to detect important therapeutic benefits. There is also the danger of false positive findings, a possibility enhanced by the likely publication bias in favour of "significant" results. There have been several instances where conflicting results from a large number of small trials have led to great uncertainty about the benefit of particular treatments. Though the results from several small trials may sometimes be reasonably combined, statistically, each clinical trial should be designed to be
